Niagen Bioscience (NASDAQ:NAGE) Given New $12.00 Price Target at HC Wainwright

Key Points

• HC Wainwright has raised its price target for Niagen Bioscience from $11.00 to $12.00, indicating a potential upside of 23.33%.
• Other analysts, including Roth Capital, have also given buy ratings, with a notable price target increase to $23.00.
• The company's recent earnings report showed a profit of $0.04 EPS, surpassing expectations, with revenue of $31.12 million.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) had its target price boosted by analysts at HC Wainwright from $11.00 to $12.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's price objective would indicate a potential upside of 23.33% from the stock's current price.

A number of other equities analysts have also recently commented on the stock. Roth Capital reaffirmed a "buy" rating and issued a $23.00 target price (up from $10.00) on shares of Niagen Bioscience in a report on Friday, June 6th. Wall Street Zen lowered shares of Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 2nd. Finally, Canaccord Genuity Group lifted their price objective on shares of Niagen Bioscience from $13.00 to $16.00 and gave the company a "buy" rating in a research report on Tuesday, June 10th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $13.42.

Niagen Bioscience Price Performance

Shares of Niagen Bioscience stock opened at $9.73 on Monday. The firm's fifty day simple moving average is $11.77 and its 200-day simple moving average is $8.30. The stock has a market capitalization of $775.97 million, a price-to-earnings ratio of 46.34 and a beta of 2.12. Niagen Bioscience has a 12 month low of $2.69 and a 12 month high of $14.69.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. The business had revenue of $31.12 million for the quarter, compared to analysts' expectations of $28.55 million. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%.

Institutional Investors Weigh In On Niagen Bioscience

Institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its position in shares of Niagen Bioscience by 80.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 122,922 shares of the company's stock worth $652,000 after purchasing an additional 54,969 shares in the last quarter. EAM Investors LLC purchased a new stake in shares of Niagen Bioscience during the 4th quarter worth $746,000. Teton Advisors Inc. boosted its position in shares of Niagen Bioscience by 25.0% during the 4th quarter. Teton Advisors Inc. now owns 25,000 shares of the company's stock worth $133,000 after purchasing an additional 5,000 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of Niagen Bioscience during the 4th quarter worth $522,000. Finally, Walleye Capital LLC purchased a new stake in shares of Niagen Bioscience during the 4th quarter worth $215,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.